Novo seems to believe that payors will pay a premium for a new product just because it is new, when in reality payors are recognizing what everyone else has, in that these so-called new drugs don't offer a compelling case for premium reimbursement.
Novo seems to believe that payors will pay a premium for a new product just because it is new, when in reality payors are recognizing what everyone else has, in that these so-called new drugs don't offer a compelling case for premium reimbursement.
Share this Article
Comment on this Article
Recommended
Please to comment